Clinical Trials Logo

Filter by:
NCT ID: NCT02298686 Withdrawn - Developmental Delay Clinical Trials

Biomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo)

BioSanfilippo
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the ear-ly and sensitive diagnosis of Sanfilippo Disease Type A-B-C-D from blood (plasma)

NCT ID: NCT02298673 Withdrawn - Clinical trials for Skeletal Abnormalities

Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)

BioML
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Mucolipidosis Disorder type I,II,III or IV from blood (plasma)

NCT ID: NCT02298647 Withdrawn - Seizures Clinical Trials

Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)

BioGM1/BioGM2
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the ear-ly and sensitive diagnosis of GM1/GM2 from blood

NCT ID: NCT02298634 Withdrawn - Splenomegaly Clinical Trials

Biomarker for Farber Disease (BioFarber)

BioFarber
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Farber disease from the blood

NCT ID: NCT02214030 Withdrawn - Clinical trials for Other Vascular Adverse Event

Efficacy Study of Assiut Femoral Compression Device Versus Manual Compression in the Achievement of Hemostasis

Start date: September 2013
Phase: N/A
Study type: Interventional

This study was performed to evaluate the safety and efficacy of a locally designed Assiut Femoral Compression Device (AFCD) versus manual compression (MC). Femoral compression devices have been developed thorough the past decades without being strongly implemented in the catheterization laboratory. Their limited adoption reflects concerns of high cost and conflicting data regarding their safety

NCT ID: NCT02121951 Withdrawn - Clinical trials for Regional Anesthesia Morbidity

Quadratus Lumborum Block for Percutaneous Nephrostomy

QLB
Start date: May 2014
Phase: Phase 4
Study type: Interventional

Percutaneous nephrostomy (PCN) is one of the interventions in the radiology department in which pain control is necessary. Quadratus Lumborum (QL) block will be tried to limit the use of systemic analgesics and its accompanying untoward effects in those frail patients requiring PCN that is performed in the prone position.

NCT ID: NCT02103946 Withdrawn - Breast Cancer Clinical Trials

Serratus Anterior Plane Block Versus Paravertebral Block for Postmastectomy Analgesia

SAM
Start date: April 2014
Phase: N/A
Study type: Interventional

ًًًُُُُThe investigators are testing the efficacy of a new novel technique; serratus anterior plane block, for preventing postoperative pain after breast surgery for cancer. This block will be compared with the well-established paravertebral block.

NCT ID: NCT02101177 Withdrawn - Chronic Hepatitis C Clinical Trials

Evaluation of the National Treatment Program of Hepatitis C in Egypt

eNTC
Start date: April 2014
Phase: N/A
Study type: Observational

The aim of the study is to analyse data coming from two treatment centres of the National Treatment Program Centres of hepatitis C in Egypt

NCT ID: NCT02099604 Withdrawn - Chronic Hepatitis C Clinical Trials

Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C

ViZIR
Start date: April 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to show the superiority of a 4 weeks lead-in phase of Vitamin D followed by a 48 weeks combination of Vitamin D with PEG-IFN plus RBV in comparison with standard PEG-IFN + RBV in untreated Egyptian patients with chronic hepatitis C, on the sustained virological response (SVR) at 3 months after end of treatment (week 60).

NCT ID: NCT01871662 Withdrawn - Clinical trials for Hepatitis C, Chronic

Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C

HEPASIL
Start date: August 2013
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to explore whether silibinin plus ribavirin with/without peg-interferon can be more effective than the peg-interferon plus ribavirin based standard of care (SoC) in the treatment of patients infected with hepatitis C virus genotype 4.